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1 Drug description 
Generic/Brand name/ATC code:  
Obinutuzumab/Gazyva
®
/L01XC15 
Developer/Company:  
Hoffmann-La Roche Inc. 
Description:  
Obinutuzumab (afutuzumab, GA101, RO5072759) is a type II, glycoengi-
neered, humanised anti-CD20 monoclonal antibody with potential antineo-
plastic activity. It selectively binds to the extracellular domain of the human 
CD20 antigen on malignant human B cells and promotes antibody-
dependent cell-mediated cytotoxicity and complement-dependent cytotoxi-
city [1, 2]. 
Obinutuzumab is available in single-use vials containing 1,000 mg/40 ml (25 
mg/ml). The recommended dose regimen for six cycles (28-day cycles) is:  
 100 mg on day 1 cycle 1  
 900 mg on day 2 cycle 1  
 1000 mg on day 8 and 15 of cycle 1  
 1000 mg on day 1 of cycles 2–6 [3]. 
 
Gazyva
®
 should be administered as intravenous infusion, not as an 
intravenous push or bolus. Furthermore, premedication with glucocorticoid, 
acetaminophen and anti-histamine is recommended. Warnings in terms of  
hepatitis B virus reactivation causing hepatic failure or death, development 
of progressive multifocal leukoencephalopathy, Tumour Lysis Syndrome, 
neutropenia and thrombocytopenia have been formulated and are 
incorporated in the U.S. Food and Drug Administration (FDA) drug label 
information [3]. 
 
 
2 Indication 
Obinutuzumab is indicated for the treatment of previously untreated chron-
ic lymphocytic leukaemia (CLL) patients. 
 
 
3 Current regulatory status 
On 10 October 2012, orphan designation (EU/3/12/1054) was granted by the 
European Commission for obinutuzumab for the treatment of CLL [4], but 
obinutuzumab is not yet licensed in Europe. 
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The FDA approved obinutuzumab for use in combination with chlorambu-
cil for the treatment of patients with previously untreated CLL on 1 No-
vember 2013 [5]. 
 
4 Burden of disease 
CLL belongs to the group of indolent B-cell non-Hodgkin lymphomas 
(NHL) and is the most common type of adult leukaemia in Western coun-
tries, accounting for approximately 25% to 30% of all leukaemias [6]. The 
median age at diagnosis is 72 years [7], and 70% of patients are older than 65 
years at diagnosis. CLL is rarely seen in younger persons. Fewer than 2% of 
patients are younger than 45 years at the time of diagnosis. The male to fe-
male ratio is 2:1 [6, 8]. 
Risk factors for developing CLL include older age, male sex, white ethnicity, 
family history of CLL or other blood and bone marrow cancers and exposure 
to certain chemicals, such as herbicides and insecticides [9]. 
 
In the majority of cases CLL is diagnosed incidentally by routine complete 
blood count examination, because most patients are asymptomatic at the 
time of diagnosis. Diagnosis is established by blood counts, blood smears 
and immunophenotyping of circulating B-lymphocytes [10]. The most 
common symptom is lymphadenopathy, followed by so-called “B” symp-
toms, including fever, night sweats and weight loss. The life expectancy of 
patients with early-stage disease at diagnosis is greater than ten years but 
decreases with advanced disease at diagnosis [11, 12]. 
 
There are two classification systems for the clinical staging of CLL, depend-
ing on standard laboratory tests and physical examination, including the Rai 
classification and the Binet staging system. The Rai classification distin-
guishes low (formerly Rai stage 0), intermediate (formerly Rai stage I or II) 
and high (formerly Rai stage IV and V) risk disease, whereas the Binet stag-
ing is subdivided into stages A, B and C [13].  
 
Table 1: Binet staging system for CLL (from [14]) 
Stage  Description  
A Two or less lymphoid-bearing areas enlarged*  
B Three or more lymphoid-bearing areas enlarged*  
C 
Presence of anaemia (Hgb <10.0 g/dl) or thrombocytopenia (platelet 
count <100,000/μl)  
* Five lymphoid bearing areas are possible: cervical, axillary, inguino-
femoral, spleen and liver. 
 
The initiation of treatment is not recommended for asymptomatic early-
stage disease (Rai 0, Binet A). In these patients a watch-and-wait strategy 
with controls of blood cell counts and clinical examination every three to six 
months is recommended until there is evidence of disease progression. In 
patients with intermediate and high-risk disease, according to the Rai classi-
fication as well as patients with Binet stage B or C disease, the initiation of 
treatment is recommended, whereas some patients with intermediate disease 
or Binet stage B may also be monitored until disease progresses [15]. 
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Cytogenetic abnormalities are present in about 80% of patients with previ-
ously untreated CLL. These cytogenetic abnormalities also influence prog-
nosis. The most common abnormalities include: 
 Del (13q) (55%) 
 Del (11q) (18%) 
 Trisomy 12 (16%) 
 Del (17p) (7%) 
 Del (6q) (7%) [16]. 
 
 
5 Current treatment 
There are various treatment options for CLL depending on disease stage, pa-
tient’s age, presence of cytogenetic lesions or concomitant diseases. Patients 
diagnosed with CLL at an early stage should be observed only [15]. Current-
ly, fludarabine, cyclophosphamide, and rituximab (FCR) immunochemo-
therapy is the standard of care for previously untreated patients with CLL. 
However, this regimen is in general neither appropriate for patients with 
impaired renal function nor for patients above the age of 65 years nor for pa-
tients with a comorbidity burden (CIRS >6) [17]. 
 
The regimen in first-line therapy varies along with patient characteristics 
such as age, genetic mutations or comorbidity [15]. Therapy options include: 
 
 Alkylating agents: chlorambucil, bendamustine, cyclophosphamide 
 Anthracyclines (e.g. adriamycine), anthrachinolones (e.g. 
mitoxantrone) 
 Purine/pyrimidine nucleoside analogues: fludarabine, cladribine, 
pentostatin 
 Monoclonal antibodies: rituximab, alemtuzumab 
 Immunomodulation drugs: lenalidomide 
 Corticosteroid drugs: prednisone [15, 17-19]. 
 
Combination or single-agent therapy is indicated depending on patient 
characteristics. In the past few years, antibody monotherapy and the addi-
tion of monoclonal antibodies to chemotherapy have moved into the focus of 
interest. For example, rituximab in addition to chemotherapy is an effective 
treatment option for CLL patients [20]. 
 
Treatment options especially for older patients with CLL who have 
comorbidities include: 
 Chlorambucil plus rituximab 
 Bendamustine plus rituximab 
 Pulsed intermittent single-agent chlorambucil (e.g. a single oral dose 
of 0.8 mg/kg every four weeks, adjusted as needed) 
 Lower-dose fludarabine (25 mg/m2 IV for three consecutive days every 
month) 
 FR (Fludarabine plus rituximab) 
 Tyrosine kinase inhibitors (e.g. ibrutinib), PI3K inhibitors (e.g. 
idelalisib), bcl-2 inhibitors (already licensed or expected to be licensed 
soon in the U.S.) [21]. 
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6 Evidence 
A literature search was conducted on the 16
th
 of April 2014 in four databases 
(Medline, Embase, CRD, Cochrane Central). Search terms were “chronic 
lymphocytic leukaemia”, “obinutuzumab”, “gazyva” and “afutuzumab”. 
Overall, 254 references were identified through literature search. The man-
ufacturer additionally submitted five articles, which had already been 
identified through literature search. Eligible for inclusion were phase III 
trials (full text, abstracts) and phase II studies published as full text but 
also other study designs such as results from compassionate-use pro-
grammes or meta-analyses. After applying these inclusion criteria, one phase 
III trial and no phase II trial were included in this report. 
 
literature search in four 
databases: 254 hits 
 
included: one phase III 
trial 
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6.1 Efficacy and safety – phase III studies 
Table 1: Summary of efficacy 
Study title  
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions [22-24] 
Study  
identifier 
NCT01010061 
Design Open-label, three-group study, randomisation in a 1:2:2 ratio, stratification according 
to geographic region and Binet stage, multinational (26 countries, 189 centres), 
patients who progress during or within six months of end of Chlorambucil treatment 
have the opportunity to cross over 
Duration  Enrolment: April 2010–July 2012 
Median follow-up: 14.2 months as of July 2012 [17] 
Cut-off dates for analyses: July/August 2012 (stage 1 primary 
analysis), May 2013 (stage 1 updated analysis, stage 2 interim 
analysis) 
Hypothesis  Stage 1a: obinutuzumab in combination with chlorambucil vs. chlorambucil alone 
(O-Clb vs. Clb): superiority of O-Clb over Clb for initial application 
 Stage 1b: rituximab in combination with chlorambucil vs. chlorambucil alone (R-Clb 
vs. Clb): superiority of R-Clb over Clb  
 Stage 2: obinutuzumab in combination with chlorambucil vs. rituximab in 
combination with chlorambucil (O-Clb vs. R-Clb): superiority of O-Clb over R-Clb 
Funding Hoffmann-La Roche Inc. 
Treatment 
groups 
Stage 1a: O-Clb vs. Clb (obinutuzumab in combination with chlorambucil vs. 
chlorambucil alone) 
Stage 1b: R-Clb vs. Clb (rituximab in combination with chlorambucil vs. chlorambucil 
alone) 
Stage 2: O-Clb vs. R-Clb (obinutuzumab in combination with chlorambucil vs. 
rituximab in combination with chlorambucil) 
Obinutuzumab + 
chlorambucil  
(stage 1a n=238 
stage 2 n=333) 
Obinutuzumab administered intravenously at a dose of 1000 mg 
on days 1, 8, and 15 of cycle 1 and on day 1 of cycles 2 through 6 
+ 
chlorambucil administered orally at a dose of 0.5 mg per 
kilogram of body weight on days 1 and 15 of each cycle 
Rituximab+ 
chlorambucil 
(stage 1b n=233 
stage 2 n=330) 
Rituximab administered intravenously at a dose of 375 mg/m2 of 
body-surface area on day 1 of cycle 1 and 500 mg/m2 on day 1 of 
cycles 2 through 6 
+ 
chlorambucil administered orally at a dose of 0.5 mg per 
kilogram of body weight on days 1 and 15 of each cycle 
Chlorambucil 
(stage 1a/1b n=118) 
Chlorambucil administered orally at a dose of 0.5 mg per 
kilogram of body weight on days 1 and 15 of each cycle 
Endpoints 
and 
definitions 
Progression free 
survival 
(primary outcome) 
PFS Time from randomisation to the first occurrence of 
progression, relapse or death due to any cause 
Overall survival OS Time between the date of randomisation and the date of 
death due to any cause 
Event-free survival EFS Time between the date of randomisation and the date of 
disease progression/relapse, death or start of new anti-
leukaemia treatment 
End of treatment 
response 
- Response occurring at the end of treatment before start 
of new anti-leukaemia treatment 
Complete response CR Date of first recorded complete response to the date of 
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disease progression or death due to any cause 
Partial response PR Date of first recorded partial response to the date of 
disease progression or death due to any cause 
Disease-free 
survival 
- For all patients with complete response at any time from 
56 days after end of treatment onward 
Time to new anti-
leukaemic therapy 
- Time between  the date of randomisation and the date 
of first intake of re-treatment or new leukaemic therapy 
Quality of life QoL Assessed with the EORTC QLQC30 
Results and analysis 
Analysis  
description 
ITT  
Primary analysis included treatment comparison using a two-sided stratified (by Binet 
stage) log-rank test and estimation of median times with 95% CI; secondary end points 
were analysed with a two-sided test at a 5% alpha level 
Analysis  
population 
Inclusion  Documented CD20 + B-CLL 
 Previously untreated CLL requiring treatment 
 Total CIRS score >6 and/or creatinine clearance <70 ml/min 
 Life expectancy >6 months 
Exclusion  Previous CLL therapy 
 Transformation of CLL to aggressive NHL 
 One or more individual organ/system impairment score(s) of 4 
as assessed by the CIRS definition 
 Inadequate renal function: creatinine clearance <30 ml/min 
 Inadequate liver function 
 Active bacterial, viral or fungal infection requiring systemic 
treatment 
Characteristics 
[22] 
 Age – median (range): 
O-Clb vs. Clb: 74 (39-88) vs. 72 (43-87) 
R-Clb vs. Clb: 73 (40-90) vs. 72 (43-87) 
O-Clb vs. R-Clb: 74 (39-89) vs. 73 (40-90) 
 CIRS Score – median (range): 
O-Clb vs. Clb: 8 (1-20) vs. 8 (0-18) 
R-Clb vs. Clb: 8 (0-18) vs. 8 (0-18) 
O-Clb vs. R-Clb: 8 (0-22) vs. 8 (0-18) 
 Median calculated creatinine clearance (ml/min): 
O-Clb vs. Clb: 61.4 vs. 63.8 
R-Clb vs. Clb: 61.8 vs. 63.8 
O-Clb vs. R-Clb: 62.5 vs. 62.6 
 Binet stage A, n (%): 
O-Clb vs. Clb: 55 (23) vs. 24 (20) 
R-Clb vs. Clb: 49 (21) vs. 24 (20) 
O-Clb vs. R-Clb: 74 (22) vs. 74 (22) 
 Binet stage B, n (%): 
O-Clb vs. Clb: 98 (41) vs. 50 (42) 
R-Clb vs. Clb: 100 (43) vs. 50 (42) 
O-Clb vs. R-Clb: 142 (43) vs. 135 (41) 
 Binet stage C, n (%): 
O-Clb vs. Clb: 85 (36) vs. 44 (37) 
R-Clb vs. Clb: 84 (36) vs. 44 (37) 
O-Clb vs. R-Clb: 117 (35) vs. 121 (37) 
 Unmutated IGHV, n/total n (%): 
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O-Clb vs. Clb: 129/210 (61) vs. 58/99 (59) 
R-Clb vs. Clb: 126/204 (62) vs. 58/100 (58) 
O-Clb vs. R-Clb: 188/305 (62) vs. 182/298 (61) 
 Del (17p) on FISH, n/total n (%): 
O-Clb vs. Clb: 16/203 (8) vs. 10/96 (10) 
R-Clb vs. Clb: 9/196 (5) vs. 10/97 (10) 
O-Clb vs. R-Clb: 22/295 (7) vs. 20/287 (7) 
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Descriptive 
statistics 
and 
estimated 
variability 
 
May 2013 
[22, 24] 
Treatment group Stage 1a Stage 1b Stage 2 
O-Clb Clb R-Clb Clb O-Clb R-Clb 
Number of subjects N=238 N=118 N=233 N=118 N=333 N=330 
Median PFS, months (SI-
assessed) [22] 
Median PFS, months (IRC-
assessed, secondary 
endpoint) [24] 
26.7 
 
27.2 
11.1 
 
11.2 
16.3 
 
16.1 
11.1 
 
11.2 
26.7 
 
26.7 
15.2 
 
14.9 
Patients with a complete 
response (%) [22] 
22.3 0 7.3 0 20.7 7.0 
Patients with a partial 
response (%) [22] 
55.0 31.4 58.4 31.4 57.7 58.1 
Event-free survival, 
median in months (IRC-
assessed) [24] 
 
26.1 
 
10.8 
 
15.4 
 
10.8 
 
26.1 
 
14.3 
Time to new anti-
leukaemic therapy, median 
in months (IRC-assessed) 
[24] 
 
NR 
 
14.8 
 
30.8 
 
14.8 
 
NR 
 
30.8 
 
July 2012 
[23] 
Event-free survival, 
median in months  
23.0 
 
10.6 
 
NR NR 
End of treatment 
response, %  
95% CI 
75.5 
 
69.1-81.1 
30.2 
 
21.7-39.9 
NR NR 
Time to new anti-
leukaemic therapy, median 
in months 
NR 
 
14.8 
 
NR NR 
Effect 
estimate per 
comparison 
 
Comparison groups  O-Clb vs Clb R-Clb vs Clb O-Clb vs R-Clb 
Median PFS [22] HR 0.18 0.44 0.39 
95% CI 0.13-0.24 0.34-0.57 0.31-0.49 
P value  <0.001 <0.001 <0.001 
Probability of OS [22] HR 0.41 0.66 0.66 
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95% CI 0.23-0.74 0.39-1.11 0.41-1.06 
P value  0.002 0.11 0.08 
Event-free survival [24] HR 0.19 0.39 0.43 
95% CI 0.14-0.25 0.30-0.51 0.34-0.54 
P value  <0.0001 <0.0001 <0.0001 
Time to next anti-
leukaemic therapy [24] 
HR 0.24 0.34 0.59 
95% CI 0.16-0.35 0.24-0.48 0.42-0.82 
P value  <0.0001 <0.0001 0.0018 
Abbreviations: CI = confidence interval, CIRS = Cumulative Illness Rating Scale, Clb = chlorambucil, CLL = chronic lymphocytic leukaemia, EORTC QLQ-C30 = European Organisation for 
Research and Treatment of Cancer QLQ-C30 Questionnaire, FISH = fluorescence in situ hybridisation, HR = hazard ratio, IGHV = immunoglobulin heavy-chain variable region gene, 
IRC = Independent Radiologic Assessment Committee, ml/min = millilitre per minute, n = number, NHL = Non-Hodgkin Lymphoma, NR = not reported, O-Clb = obinutuzumab-
chlorambucil, OS = overall survival, PFS = progression free survival, R-Clb = rituximab-chlorambucil, SI = site investigator 
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Table 2: Adverse events 
NCT01010061 
AEs of Grade 3 or higher [22]1 
Stage 1a Stage 1b Stage 2 
O-Clb (n=241) Clb (n=116) R-Clb (n=225) Clb (n=116) O-Clb (n=336) R-Clb (n=321) 
Any event, n (%) 175 (73) 58 (50) 125 (56) 58 (50) 235 (70) 177 (55) 
Infusion-related reactions, n (%) 51 (21) - 9 (4) - 67 (20) 12 (4) 
Neutropenia, n (%) 84 (35) 18 (16) 60 (27) 18 (16) 111 (33) 91 (28) 
Anaemia, n (%) 11 (5) 5 (4) 10 (4) 5 (4) 14 (4) 12 (4) 
Thrombocytopenia, n (%) 27 (11) 5 (4) 8 (4) 5 (4) 35 (10) 10 (3) 
Leukopenia, n (%) 13 (5) 0 3 (1) 0 15 (4) 3 (1) 
Infections, n (%) 27 (11) 16 (14) 30 (13) 16 (14) 40 (12) 44 (14) 
Pneumonia, n (%) 8 (3) 4 (3) 11 (5) 4 (3) 13 (4) 17 (5) 
Febrile neutropenia, n (%) 4 (2) 5 (4) 4 (2) 5 (4) 8 (2) 4 (1) 
Other serious AEs [24]2  
Neoplasm, n (%) 17 (7) 5 (4) 16 (7) 5 (4) 19 (6) 18 (6) 
Respiratory tract infection, n (%) 2 (<1) 3 (3) 2 (<1) 3 (3) 3 (<1) 2 (<1) 
Sepsis, n (%) 0 3 (3) 0 3 (3) 1 (<1) 1 (<1) 
Cardiac failure, n (%) 3 (1) 2 (2) 0 2 (2) 4 (1) 1 (<1) 
Urinary tract infection, n (%) 3 (1) 1 (<1) 0 1 (<1) 3 (<1) 1 (<1) 
Cerebrovascular accident, n (%) 3 (1) 0 1 (<1) 0 3 (<1) 1 (<1) 
Abbreviations: AE = adverse event, Clb = chlorambucil, n = number, O-Clb = obinutuzumab-chlorambucil, R-Clb = rituximab-chlorambucil 
 
 
                                                             
1
 Data for the incidence rate of 3% or higher in any treatment group [22] 
2
 Data for the incidence rate of ≥1% in any treatment arm [24] 
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A three arm, open-label, multicentre phase III study [22] examined the effi-
cacy and safety of obinutuzumab in combination with chlorambucil and 
chlorambucil alone, rituximab in combination with chlorambucil and chlo-
rambucil alone as well as obinutuzumab in combination with chlorambucil 
and rituximab in combination with chlorambucil in patients with CLL. 781 
patients were randomly assigned.  
The study included 2 stages: stage 1 randomised patients into three study 
arms on a 1:2:2 basis (randomisation to the chlorambucil alone arm, the 
obinutuzumab-chlorambucil or the rituximab-chlorambucil arm) and stage 
2 randomised additional patients at a 1:1 ratio (randomisation continued on-
ly to the obinutuzumab-chlorambucil or the rituximab-chlorambucil arm 
and was stopped to the chlorambucil alone arm). Randomisation for both 
stages was stratified by Binet stage at baseline and geographic region. The 
primary analysis of stage 1 was performed in July/August 2012, whereas an 
updated analysis of stage 1 and the interim analysis of stage 2 were done in 
May 2013. Patients had to be previously untreated but requiring treatment 
and had to had a total CIRS score
3
 of > 6 and/or a creatinine clearance <70 
ml/min. Included patients had a median age of 73 years, a creatinine clear-
ance of 62 ml/min and a CIRS score of 8. 21% of the patients were in Binet 
stage A, 42% in Binet stage B and 36% in Binet stage C. 
Treatment with obinutuzumab–chlorambucil or rituximab–chlorambucil 
provided a significant improvement concerning median PFS, the primary 
outcome, as compared with chlorambucil monotherapy (26.7 months with 
obinutuzumab–chlorambucil vs. 11.1 months with chlorambucil alone, HR 
0.18, 95% CI 0.13-0.24, p<0.001 and 16.3 months with rituximab–
chlorambucil vs. 11.1 months with chlorambucil alone, HR 0.44, 95% CI 
0.34-0.57, p<0.001). Treatment with obinutuzumab–chlorambucil compared 
with rituximab–chlorambucil showed also a PFS benefit for the 
obinutuzumab–chlorambucil group (median PFS 26.7 vs. 15.2 months, HR 
0.39, 95% CI 0.31-0.49, p<0.001). Subgroup analyses showed that this bene-
fit was consistent across most patient subgroups (age, sex, Binet stage, circu-
lating lymphocyte count, total CIRS score) with the only exception of pa-
tients with del (17p) mutations [24]. 
Concerning OS, obinutuzumab–chlorambucil was associated with better re-
sults compared with chlorambucil monotherapy (HR 0.41, 95% CI 0.23-0.74, 
p=0.002). No significant benefit was seen for rituximab–chlorambucil over 
chlorambucil alone (HR 0.66, 95% CI 0.39-1.11, p=0.11). No benefit was 
noted for obinutuzumab–chlorambucil compared with rituximab–
chlorambucil (HR 0.66, 95% CI 0.41-1.06, p=0.08). The overall survival 
analysis included 22 patients from the chlorambucil monotherapy arm who 
crossed over to receive obinutuzumab–chlorambucil upon disease progres-
sion. At the time of data cut-off, none of these patients had died [23].  
                                                             
3
 The CIRS index uses a scoring system that includes 14 body system domains and a 
severity scale (0–4) for each domain. It is used to quantify the number and the se-
verity of coexisting medical conditions [17] 
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Adverse events were most frequent in treatment with obinutuzumab-
chlorambucil. Any adverse event of grade 3 or higher occurred in 73% and 
70% of all patients receiving obinutuzumab–chlorambucil in stages 1a and 
2, respectively compared with 50% and 55% in stage 1a chlorambucil mono-
therapy in patients and with stage 2 rituximab–chlorambucil patients, re-
spectively. In patients with rituximab–chlorambucil compared with chlo-
rambucil alone, 56% vs. 50% had any adverse events of grade 3 or higher. 
Neutropenia, infusion-related reactions, infections and thrombocytopenia 
occurred also more frequently in the obinutuzumab–chlorambucil group. 
Findings on quality of life were not available in the study or the supplemen-
tary appendix documents, but the authors mentioned that quality of life did 
not deteriorate due to antibody therapy in comparison to chlorambucil 
alone.  
 
6.2 Efficacy and safety – further studies 
No phase II studies were found for obinutuzumab in patients with previous-
ly untreated CLL. 
 
 
7 Estimated costs 
No cost estimates are available yet for Austria. 
In the US, cost estimates for obinutuzumab are $6,192 for one vial (1,000 
mg). Costs for 28 days are estimated at $18,576 (cycle 1) and $6,192 (cycles 
2-6) [16]. 
 
 
8 Ongoing research 
At http://clinicaltrials.gov/ and https://www.clinicaltrialsregister.eu/ctr-
search/ one ongoing phase III study investigating obinutuzumab in patients 
with CLL was found. 
 NCT01905943: A multicentre, open-label, single-arm study evaluat-
ing the safety of obinutuzumab alone or in combination with chemo-
therapy in patients with previously untreated or relapsed/refractory 
CLL. The estimated study completion date is June 2018. 
 
Several other phase I and phase II studies are currently conducted 
(NCT01414205, NCT01889797, NCT01287741). 
 
 
AEs were most frequent 
in patients treated with 
obinutuzumab-
chlorambucil 
no findings on QoL were 
available 
no phase II study found 
no cost estimates 
available for Austria 
 
one ongoing phase III 
study in patients with 
CLL 
obinutuzumab is 
investigated in different 
studies 
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9 Commentary 
On 10 October 2012, the European Commission granted orphan designation 
for obinutuzumab for the treatment of CLL, but obinutuzumab is not yet li-
censed in Europe [4]. The FDA approved obinutuzumab for use in combina-
tion with chlorambucil for the treatment of patients with previously untreat-
ed CLL on 1 November 2013 [5]. 
Obinutuzumab is the first drug approved with breakthrough therapy desig-
nation in the U.S. Breakthrough therapy designation is intended to expedite 
the development and review of drugs for serious or life-threatening condi-
tions. The criteria for breakthrough therapy designation require preliminary 
clinical evidence demonstrating that the drug may show substantial im-
provement on at least one clinically significant endpoint over available ther-
apy [25]. Breakthrough therapy designation covers all features of the fast 
track programme and involves more intensive FDA guidance on an efficient 
drug development programme [21, 23, 26]. 
A phase III study (trial divided into three stages: Stage 1a NCT01010061; 
Stage 1b NCT01998880; Stage 2 NCT02053610) examined the efficacy and 
safety of obinutuzumab in combination with chlorambucil and chlorambucil 
monotherapy, rituximab in combination with chlorambucil and chlorambu-
cil monotherapy as well as obinutuzumab combined with chlorambucil and 
rituximab in combination with chlorambucil in overall 781 previously un-
treated patients with CLL. Since patients were on average about 74 years 
old, had to have a creatine clearance of 30–69 ml/minute and a CIRS score 
of ≥6, the study population reflected older and co-morbid patients, the 
group mostly affected by CLL in clinical practice. 
 
For patients treated with obinutuzumab–chlorambucil or rituximab–
chlorambucil, median PFS (primary outcome) improved significantly com-
pared with chlorambucil monotherapy by 15.6 months and 5.2 months, re-
spectively. Treatment with obinutuzumab–chlorambucil compared with 
rituximab–chlorambucil also showed a PFS benefit for the obinutuzumab–
chlorambucil group by 11.5 months (median PFS 26.7 vs. 15.2 months, HR 
0.39, 95% CI 0.31-0.49, p<0.001). These results were consistent among in-
vestigators and independent radiologic assessors (IRC). Better results were 
also shown for obinutuzumab–chlorambucil than for rituximab–
chlorambucil in terms of complete and partial responses, but preliminary 
OS results indicated no difference between these two regimens. 
In terms of safety, the most frequent AEs grade 3 or higher were neutropenia 
(33% in the obinutuzumab-chlorambucil arm vs 28% in the rituximab-
chlorambucil arm), infusion-related reactions (20% in the obinutuzumab-
chlorambucil arm vs 4% in the rituximab-chlorambucil arm), infections 
(12% in the obinutuzumab-chlorambucil arm vs 14% in the rituximab-
chlorambucil arm) and thrombocytopenia (10% in the obinutuzumab-
chlorambucil arm vs 3% in the rituximab-chlorambucil arm) [22]. Results 
on quality of life are lacking, but authors say that no deterioration during or 
after antibody therapy happened compared to treatment with chlorambucil 
alone [22]. 
orphan designation in 
Europe, licensed in the 
USA 
obinutuzumab approved 
with breakthrough 
therapy designation by 
FDA 
phase III study on 
efficacy and safety in 
patients with untreated 
CLL 
PFS improved 
significantly in patients 
treated with 
obinutuzumab–
chlorambucil or 
rituximab–chlorambucil 
compared with 
chlorambucil alone 
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Even though the phase III study [22] is the first to deal with untreated, el-
derly patients with coexisting conditions, the drug was licensed in the U.S. 
for previously untreated patients without any restrictions in terms of pa-
tients’ populations. Rituximab in combination with fludarabine and cyclo-
phosphamide can be considered standard therapy for physically fit patients, 
but first-line treatment options for comorbid CLL patients are limited and 
mainly consisted of chlorambucil alone [7, 19, 27]. However, since anti-
CD20 monoclonal antibodies such as rituximab emerged as targeted thera-
py, a combination with chlorambucil also became a viable treatment option 
[28, 29]. The phase III study directly compared both regimens with 
obinutuzumab-chlorambucil and found improved efficacy results for this 
treatment strategy but at the expense of more AEs. 
Whether obinutuzumab offers advantages over rituximab (both drugs are 
manufactured by Roche) also for younger patients who can tolerate combi-
nation therapies with more toxic chemotherapies still needs to be deter-
mined. In addition, price considerations may influence the choice of mono-
clonal antibodies. No cost estimates are yet available for Austria, but be-
cause the patent of rituximab expired in Europe at the end of 2013 and will 
expire in the U.S. in 2015 [30, 31], new biosimilars may become available at 
potentially lower costs soon. 
Thus, assessing the CLL patients’ tolerability of aggressive chemotherapy 
will be an important driver for selecting eligible patients for obinutuzumab 
therapy. Age alone with a clear cut-off at e.g. 65–70 years will not suffice to 
determine the best course of action. There is consensus that comorbidity and 
functional status should be assessed for each patient prior to treatment initi-
ation. However, views differ as to how pre-existing comorbidities may be 
evaluated. Since the European Society for Medical Oncology mentioned 
CIRS “as a helpful tool” for assessing comorbidity [19], this instrument was 
also used in the phase III trial, but the FDA noted that it has not been vali-
dated for use in CLL or in other cancer settings [16]. 
Another consideration concerns the presence of cytogenetic abnormalities. 
Since most patients with previously untreated CLL show cytogenetic ab-
normalities and subgroup analysis indicated less benefit on PFS in patients 
with del (17p), the incorporation of biomarkers might be an important factor 
to be considered in future research [27]. Also, possible early or late toxicities 
of long-term obinutuzumab therapy need to be assessed and monitored [32]. 
 
phase III study dealing 
with untreated elderly 
patients and comparing 
treatment strategies for 
CLL 
price considerations 
may influence choice of 
treatment 
 
no cost estimates are 
available for Austria 
selection of eligible 
patients for treatment 
with obinutuzumab 
concerning comorbidity, 
functional status, etc.  
biomarkers and 
cytogenetic 
abnormalities as 
important factors for 
future research 
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